Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
FATE THERAPEUTICS INC (FATE) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
08/03/2022 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
05/04/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Stern Investor Relations, Inc."
08/04/2021 8-K Quarterly results
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "First Patients Treated with Dual-Antigen Targeting Regimen of FT596 in Combination with Rituximab. The Company is conducting a multi-center Phase 1 clinical trial of FT596, its universal, off-the-shelf, chimeric antigen receptor natural killer cell product candidate, as a monotherapy and in combination with CD20-targeted monoclonal antibody therapy for the treatment of relapsed / refractory B-cell lymphoma . The first patients have been treated at the first dose level in combination with rituximab, which enables dual-antigen targeting of both CD19 and CD20 antigens expressed on malignant B cells. In addition, the Company has initiated enrollment at the second dose level as monotherapy. FT596 is derived from a clonal master induced pluripotent stem cell line engineered with three anti-tumor..."
08/05/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/05/2019 8-K Quarterly results
Docs: "First-ever Patient Treatment with Engineered iPSC-derived Cell Product. In October 2019, two patients at the M Health Fairview University of Minnesota Medical Center were treated with FT516, the Company’s off-the-shelf natural killer cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell line engineered to express a novel high-affinity, non-cleavable CD16 Fc receptor. FT516 is the first-ever cell product in the world derived from a genetically engineered pluripotent stem cell to be administered to patients. The first patient received FT516 in combination with rituximab for the treatment of diffuse large B-cell lymphoma, and the second patient received FT516 as a monotherapy for the treatment of acute myeloid leukemia. • Initiated Enrollment at 300M Cell..."
08/07/2019 8-K/A Quarterly results
Docs: "No DLTs Reported at 300M Cell Dose Level in FT500 Monotherapy Arm. The first three patients with advanced solid tumors have been treated with multiple doses of FT500, the Company’s universal, off-the-shelf natural killer cell product candidate derived from a clonal master induced pluripotent stem cell line, at the second dose level in the study’s monotherapy arm. All three patients received three weekly doses of FT500 at 300 million cells per dose in an outpatient setting, which treatment cycle was well-tolerated with no dose-limiting toxicities and no FT500-related serious adverse events reported by investigators. All three subjects were eligible to receive a second, multi-dose treatment cycle of FT500 at 300 million cells per dose. • No DLTs Reported at 100M Cell Dose Level in FT5..."
08/06/2019 8-K Quarterly results
05/07/2019 8-K Quarterly results
Docs: "Landmark Clinical Trial of iPSC-derived Cell Product FT500 Clears Key Safety Hurdle. Three patients with advanced solid tumors have been treated with multiple doses of FT500, the Company’s universal, off-the-shelf natural killer cell product candidate derived from a clonal master induced pluripotent stem cell line, at the first dose level of 100 million cells per dose in the study’s monotherapy arm. All three patients received three once-weekly doses of FT500 in an outpatient setting in the first treatment cycle, which was well-tolerated with no dose-limiting toxicities or serious adverse events reported during the initial 28-day observation period. In accordance with the clinical protocol, all three patients advanced to a second, multi-dose treatment cycle of FT500, which has also been we..."
03/05/2019 8-K Quarterly results
Docs: "First-ever iPSC-derived Cell Product FT500 Administered to a Patient in the U.S. In November 2018, the U.S. Food and Drug Administration cleared the Company’s Investigational New Drug application for FT500, a universal, off-the-shelf natural killer cell product candidate derived from a clonal master induced pluripotent stem cell line. The landmark clinical trial is intended to assess the safety and efficacy of multiple doses of FT500 over multiple dosing cycles for the treatment of advanced solid tumors as a monotherapy and as a combination with nivolumab, pembrolizumab or atezolizumab in patients that failed to respond to, or progressed on, checkpoint inhibitor therapy. The first subject was treated with FT500 in February 2019. • Anti-Tumor Activity of FATE-NK100 Observed Across Th..."
11/01/2018 8-K Quarterly results
Docs: "Exceeded 50% Enrollment in Phase 2 PROTECT Study of ProTmune™. The randomized, controlled and double-blinded Phase 2 PROTECT study of ProTmune is over 50% enrolled. The clinical trial is intended to enroll a total of 60 adult subjects with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation . Subjects are being randomized, in a 1:1 ratio, to receive either ProTmune or a conventional matched unrelated donor hematopoietic cell graft. New clinical data from the seven subjects receiving ProTmune in the Phase 1 PROTECT study, including data on key secondary endpoints assessing disease-free survival and freedom from chronic graft-versus-host disease , cancer relapse, and death at one-year following HCT, will be featured at the 2018 American Society of Hematolo..."
08/06/2018 8-K Quarterly results
Docs: "Treated 20 th Subject in Phase 2 PROTECT Study of ProTmune™. During the second quarter of 2018, 14 subjects were treated in the randomized, controlled and double-blinded Phase 2 PROTECT study, which is intended to enroll a total of 60 adult subjects with hematologic malignancies undergoing allogeneic hematopoietic cell transplantation . Subjects in the Phase 2 PROTECT study are being randomized, in a 1:1 ratio, to receive either ProTmune, the Company’s next-generation hematopoietic cell graft, or a conventional matched unrelated donor cell graft. The Company has submitted an abstract to present clinical data from the seven subjects that were administered ProTmune in the Phase 1stage of PROTECT, including data on a key secondary endpoint assessing freedom from chronic graft-versus-hos..."
05/10/2018 8-K Quarterly results
Docs: "Reported New ProTmune™ Clinical Data Showing No Events of Cancer Relapse. In March, the Company presented additional Phase 1 PROTECT data from seven subjects administered ProTmune, the Company’s next-generation hematopoietic cell graft for patients with hematologic malignancies. As of a February 26, 2018 data cut-off, with a median time on study of 228 days, no serious adverse events related to ProTmune and no events of cancer relapse had been reported by investigators. The Company also presented immune reconstitution data, which indicate that the T- and NK cell compartments of ProTmune are functional and capable of fighting against infections and cancer. The randomized, controlled and double-blinded Phase 2 PROTECT study is currently open for enrollment at 15 U.S. centers. • ..."
03/05/2018 8-K Quarterly results
Docs: "Anti-Leukemia Activity of FATE-NK100 Observed in VOYAGE Study. In November 2017, initial clinical data of FATE-NK100, a first-in-class adaptive memory natural killer cell product, from the ongoing VOYAGE study for the treatment of refractory or relapsed acute myelogenous leukemia were presented at the Society for Immunotherapy of Cancer Annual Meeting. At two weeks following a single intravenous infusion of FATE-NK100, the subject in the first dose cohort showed nearly a 50% reduction in leukemic blasts and the subject in the second dose cohort achieved a morphologic leukemia-free state based on bone marrow biopsy. No dose limiting toxicities were reported. • Advanced FATE-NK100 through First Two Dose Cohorts of APOLLO Study. In December 2017, the APOLLO study of FATE-NK100 was init..."
11/01/2017 8-K Quarterly results
Docs: "Initial Clinical Data from VOYAGE Study of FATE-NK100 in AML to be Presented at SITC 2017. VOYAGE is an open-label, accelerated dose-escalation clinical trial of FATE-NK100, the Company’s first-in-class adaptive memory natural killer cell product candidate, for the treatment of refractory or relapsed acute myelogenous leukemia . FATE-NK100 has advanced through the first two of three dose cohorts in VOYAGE. The Company will present the post-manufacturing potency, in vivo persistence and anti-tumor activity of FATE-NK100 from the first two subjects at the Society for Immunotherapy of Cancer 32nd Annual Meeting during a poster session on November 10. The peer-reviewed non-clinical data describing the unique properties and anti-tumor activity of FATE-NK100 were published in Cancer Research in ..."
08/14/2017 8-K Quarterly results
05/15/2017 8-K Form 8-K - Current report
03/16/2017 8-K Form 8-K - Current report
08/08/2016 8-K Quarterly results
Docs: "Fate Therapeutics Reports Second Quarter 2016 Financial Results Opened Patient Enrollment in Phase 1/2 Clinical Trial of ProTmune™ for Prevention of Acute GvHD and CMV Infection"
05/09/2016 8-K Form 8-K - Current report
03/03/2016 8-K Quarterly results
Docs: "Fate Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results"
11/03/2015 8-K Quarterly results
Docs: "Fate Therapeutics Reports Third Quarter 2015 Financial Results"
08/05/2015 8-K Quarterly results
Docs: "Fate Therapeutics Reports Second Quarter 2015 Financial Results"
05/07/2015 8-K Quarterly results
Docs: "Fate Therapeutics Reports First Quarter 2015 Financial Results"
03/12/2015 8-K Quarterly results
Docs: "Fate Therapeutics Reports Year-End 2014 Financial Results"
11/12/2014 8-K Quarterly results
Docs: "Fate Therapeutics Reports Third Quarter 2014 Financial Results"
08/12/2014 8-K Quarterly results
Docs: "Fate Therapeutics Reports Second Quarter 2014 Financial Results"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy